Remove Leads Remove Patients Remove Safety Remove Side effects
article thumbnail

The debate on DTC marketing is going to heat up again

World of DTC Marketing

DTC ads do NOT lead to unnecessary Rxs. Here are some myths around DTC marketing: 1ne: DTC ads result in patients asking for prescriptions they don’t need. 3hree: DTC marketing minimizes the side effects of prescription drugs – One of the top pages within prescription drug websites continues to be “safety information.”

Marketing 285
article thumbnail

mRNA therapy could provide intracellular protein replacement for rare disease

European Pharmaceutical Review

For people with [propionic acidaemia], harmful amounts of toxic metabolites can build up in the body and lead to metabolic decompensation events and multisystemic complications. I am particularly proud of these results given that there are currently no therapeutic treatments approved for patients with this disease,” Dr Holen explained.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How Artificial Intelligence Could Be the Ultimate Weapon Against Cancer

MedCity News

With the rise of AI technologies, we could see significant advancements in cancer treatment, making it more efficient and potentially leading to a cure. By catching the disease early, patients have a higher chance of receiving successful treatment, and the cost of treatment can be significantly reduced.

article thumbnail

Leading speciality pharmacies in pharma

Pharmaceutical Technology

Speciality pharmacies play a crucial role in medication dosing, disease and side effects management, and patient care. The expert services rendered by them help in improving patient outcomes, minimising costs of the healthcare system, improving medicinal adherence and persistency and saving clinicians’ time.

article thumbnail

Novel anti-epileptic drug demonstrates efficacy

European Pharmaceutical Review

A new drug, part of a class of chemicals called potassium-channel openers, has demonstrated potential in offering relief to patients with focal epilepsy. Comparatively, patients given a placebo had on average 18 percent fewer seizures during the treatment phase of the trial, which lasted eight weeks.

article thumbnail

BMS strikes $14bn deal for Karuna Therapeutics

European Pharmaceutical Review

The deal includes Karuna’s lead asset KarXT (xanomeline-trospium), a potential first-in-class treatment for schizophrenia. KarXT targets both the M1 and M4 muscarinic receptors, resulting in a differentiated safety and efficacy profile.

article thumbnail

Three-dose vaccine prevents HIV patients getting hepatitis B

European Pharmaceutical Review

Clinical trial results presented at the US IDWeek conference, revealed a three-dose series of the HEPLISAV-B vaccine prevents hepatitis B virus (HBV) in HIV patients not previously vaccinated against or infected with the virus. At week 28, the study assessed the vaccine’s safety and levels of anti-HBV surface antibodies (HBsAbs).